Invention Grant
- Patent Title: Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
-
Application No.: US16731412Application Date: 2019-12-31
-
Publication No.: US11517622B2Publication Date: 2022-12-06
- Inventor: Sabine Hoff , Lars Rose , Dieter Zopf , Fabian Kiessling , Wiltrud Lederle , Dennis Doleschel
- Applicant: BAYER AKTIENGESELLSCHAFT
- Applicant Address: DE Leverkusen
- Assignee: BAYER AKTIENGESELLSCHAFT
- Current Assignee: BAYER AKTIENGESELLSCHAFT
- Current Assignee Address: DE Leverkusen
- Agency: Millen White Zelano and Branigan, PC
- Agent Richard J. Traverso
- Priority: EP17174169 20170602
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61P35/00 ; A61K9/00 ; A61K31/44 ; A61K39/00
Abstract:
The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
Information query
